Eyepoint Pharmaceuticals Inc (EYPT) Stock Price, Quote & News

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Duras...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 926 5000

Website: eyepoint.bio

Address:

480 Pleasant Street, Suite C-400, Watertown, United States

SinMakeMeStrong Sep. 16 at 3:09 PM

$EYPT I set a buy PT target trade so low that i didnt think it would ever be filled. Forgot about it until I just got notification that it was fufilled S3.66. You'd think I would be happy that I got it so low, however today I think unfortunately i bought high. This thing is going lower before any rebound. What i thought would be a good price a couple weeks ago, doesnt look too appealing today. Welp...i guess im in for better or worse...

0 · Reply

KimboIce Sep. 16 at 2:53 PM

$EYPT there a few nubes on this board that don’t understand how biotech market works in relation to the MMs . SP heavily controlled . Especially on Opex week . XBI flush out just bonus points for them . At some point the SP gets run up out of nowhere . Same thing happened to Ocul post P1 DR results . MM’s move in like vultures and mass buy once peak sentiment is at absolute low and RSI beaten to death . Retail has zero control of the situation.

0 · Reply

newmoneyking Sep. 16 at 2:18 PM

$EYPT buying this without news is like feeding short sellers…I’m bullish but I wouldn’t recommend buying right now. There’s a very big possibility this goes under $1 and then RS…my avg is $5.4 and have made peace with it. It’s was a bad trade.

0 · Reply

Tmoney85285 Sep. 16 at 2:04 PM

$OCUL real nice fall from grace here when you guys were so pumped about it in the mid 11s, huh? its almost like- wait for it- it…doesn’t…work. kudos though to Eylea, who got a free boost in efficacy courtesy of $OCUL and $EYPT!

0 · Reply

Tmoney85285 Sep. 16 at 1:42 PM

$OCUL the cult is strong this morning. might be the most clueless of the bunch minus JJ, who knows literally nothing. guys, its not hard. $EYPT sealed your fate.

0 · Reply

newmoneyking Sep. 16 at 1:37 PM

$EYPT this should have SSR on today, thus a little rebound here and there. Could be wrong.

1 · Reply

BLtheKid Sep. 16 at 1:30 PM

$EYPT drkyle clown blocked

2 · Reply

DrKyle Sep. 16 at 11:43 AM

$EYPT today shouldn't be as bad...likely 3.35-3.45 close

0 · Reply

SecoTrader Sep. 16 at 11:21 AM

$EYPT yeah yesterday was indeed hard to endure. I am expecting a significant rebound today, if Mr. Market allows for it LOL

0 · Reply

hellomynameiz Sep. 16 at 10:23 AM

$EYPT the stock has been a repeat kick in the nuts

0 · Reply

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sep 15, 2026, 7:00 AM EDT - 1 day ago

EyePoint Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 10, 2026, 10:20 AM EDT - 6 days ago

EyePoint Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2026, 8:00 AM EDT - 7 days ago

EyePoint Transcript: Citigroup’s Biopharma Back to School Summit 2026

Sep 9, 2026, 7:00 AM EDT - 7 days ago

EyePoint Slides: Corporate presentation

Sep 2, 2026, 7:00 AM EDT - 14 days ago

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

2026-09-02T09:50:08.000Z - 14 days ago

EyePoint downgraded to Hold from Buy at TD Cowen

Aug 28, 2026, 2:11 PM EDT - 18 days ago

EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law

2026-08-19T08:25:22.000Z - 4 weeks ago

EyePoint price target lowered to $20 from $43 at Jones

2026-08-18T12:05:57.000Z - 4 weeks ago

EyePoint downgraded to Neutral from Buy at Chardan

2026-08-18T10:10:15.000Z - 4 weeks ago

EyePoint downgraded to Neutral from Buy at H.C. Wainwright

2026-08-18T10:00:23.000Z - 4 weeks ago

EyePoint price target lowered to $17 from $35 at Citi

2026-08-18T08:35:11.000Z - 4 weeks ago

EyePoint downgraded to Sector Perform from Outperform at RBC Capital

2026-08-18T00:55:19.000Z - 4 weeks ago

EyePoint downgraded to Sector Perform from Outperform at RBC Capital

2026-08-17T20:25:34.000Z - 4 weeks ago

Clear Street sees less competition for Ocular after EyePoint miss

OCUL

2026-08-17T19:45:07.000Z - 4 weeks ago

Laidlaw trims EyePoint target, still sees high chance of approval

2026-08-17T19:40:14.000Z - 4 weeks ago

Laidlaw trims EyePoint target, still sees high change of approval

2026-08-17T18:15:14.000Z - 4 weeks ago

B. Riley views EyePoint study miss as positive for 4D Molecular

FDMT

2026-08-17T16:40:40.000Z - 4 weeks ago

EyePoint price target lowered to $8 from $30 at Jefferies

2026-08-17T16:32:24.000Z - 4 weeks ago

Why Is EyePoint Pharmaceuticals (EYPT) Stock Down 69% Today?

2026-08-17T15:55:07.000Z - 4 weeks ago

EyePoint downgraded to Neutral from Overweight at JPMorgan

Aug 17, 2026, 11:14 AM EDT - 4 weeks ago

EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.

2026-08-17T13:30:09.000Z - 4 weeks ago

EyePoint downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-08-17T13:00:45.000Z - 4 weeks ago

Morning Movers: EyePoint plummets following LUGANO trial results

BABA CRGO HTHT LHX MU SNDK SOFI

Aug 17, 2026, 8:00 AM EDT - 4 weeks ago

EyePoint Transcript: Study result

Aug 17, 2026, 8:00 AM EDT - 4 weeks ago

EyePoint Press release: Study result

Aug 17, 2026, 8:00 AM EDT - 4 weeks ago

EyePoint Slides: Study result

Aug 17, 2026, 7:16 AM EDT - 4 weeks ago

EyePoint's eye drug misses main goal in late-stage trial

Aug 17, 2026, 7:00 AM EDT - 4 weeks ago

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

Aug 14, 2026, 4:32 PM EDT - 4 weeks ago

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aug 5, 2026, 7:00 AM EDT - 6 weeks ago

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Aug 5, 2026, 7:00 AM EDT - 6 weeks ago

EyePoint Earnings release: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 6 weeks ago

EyePoint Quarterly report: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 6 weeks ago

EyePoint Slides: Investor presentation

Jul 30, 2026, 7:00 AM EDT - 6 weeks ago

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

Jul 13, 2026, 7:00 AM EDT - 2 months ago

EyePoint Appoints Tarek S. Hassan, M.D.

Jul 2, 2026, 8:20 AM EDT - 2 months ago

Robinhood and 4 More Stocks That Were Just Added to This Firm's ‘Top Picks' List

HOOD EHC ERAS MU ORCL

Jun 9, 2026, 11:20 AM EDT - 3 months ago

EyePoint Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 4:55 PM EDT - 3 months ago

EyePoint Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 9:00 AM EDT - 3 months ago

EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 19, 2026, 7:00 AM EDT - 4 months ago

EyePoint Announces Participation at Upcoming Investor Conferences

May 14, 2026, 9:51 AM EDT - 4 months ago

EyePoint's late-stage eye drug trials to continue after safety panel review

May 14, 2026, 7:00 AM EDT - 4 months ago

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

May 6, 2026, 8:30 AM EDT - 4 months ago

EyePoint Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 months ago

EyePoint Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 months ago

EyePoint Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 4 months ago

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Apr 29, 2026, 7:00 AM EDT - 4 months ago

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

Apr 27, 2026, 8:00 AM EDT - 4 months ago

EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

EyePoint Proxy statement: Proxy filing

Apr 23, 2026, 7:00 AM EDT - 4 months ago

EyePoint Slides: Investor presentation

Mar 25, 2026, 8:45 AM EDT - 5 months ago

EyePoint Transcript: RBC Capital Markets Virtual Ophthalmology Conference

Mar 20, 2026, 5:24 PM EDT - 5 months ago

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

OCUL

Mar 4, 2026, 8:30 AM EST - 6 months ago

EyePoint Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

EyePoint Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

EyePoint Earnings release: Q4 2025

Mar 4, 2026, 7:00 AM EST - 6 months ago

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

Mar 3, 2026, 2:30 PM EST - 6 months ago

EyePoint Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 6 months ago

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

Mar 2, 2026, 7:00 AM EST - 6 months ago

EyePoint Slides: Investor presentation

Feb 25, 2026, 7:00 AM EST - 6 months ago

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

Feb 18, 2026, 7:00 AM EST - 7 months ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer

Feb 12, 2026, 11:00 AM EST - 7 months ago

EyePoint Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 7 months ago

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 13, 2026, 10:30 AM EST - 8 months ago

EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 8 months ago

EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 8 months ago

EyePoint Slides: Investor presentation

Jan 7, 2026, 7:00 AM EST - 8 months ago

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Dec 17, 2025, 7:00 AM EST - 9 months ago

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 19, 2025, 7:00 AM EST - 10 months ago

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Nov 12, 2025, 10:40 AM EST - 10 months ago

EyePoint Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:40 AM EST - 10 months ago

EyePoint Slides: FY 2025

Nov 10, 2025, 10:30 AM EST - 10 months ago

EyePoint Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 8:30 AM EST - 10 months ago

EyePoint Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

EyePoint Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

EyePoint Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Oct 29, 2025, 7:00 AM EDT - 10 months ago

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 14, 2025, 10:43 PM EDT - 11 months ago

EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 4:35 PM EDT - 11 months ago

EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:01 PM EDT - 11 months ago

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

Sep 3, 2025, 2:45 PM EDT - 1 year ago

EyePoint Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 2:30 PM EDT - 1 year ago

EyePoint Transcript: Citi's Biopharma Back to School Conference

Aug 13, 2025, 10:00 AM EDT - 1 year ago

EyePoint Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q2 2025

Aug 6, 2025, 7:30 AM EDT - 1 year ago

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 7:00 AM EDT - 1 year ago

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Jul 30, 2025, 7:00 AM EDT - 1 year ago

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 29, 2025, 7:00 AM EDT - 1 year ago

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Jun 10, 2025, 2:40 PM EDT - 1 year ago

EyePoint Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 2:40 PM EDT - 1 year ago

EyePoint Slides: Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025, 8:30 AM EDT - 1 year ago

EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint Slides: Investor Presentation

May 20, 2025, 10:00 AM EDT - 1 year ago

EyePoint Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 16, 2025, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 9, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Apr 30, 2025, 7:00 AM EDT - 1 year ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

SinMakeMeStrong Sep. 16 at 3:09 PM

0 · Reply

KimboIce Sep. 16 at 2:53 PM

0 · Reply

newmoneyking Sep. 16 at 2:18 PM

0 · Reply

Tmoney85285 Sep. 16 at 2:04 PM

0 · Reply

Tmoney85285 Sep. 16 at 1:42 PM

$OCUL the cult is strong this morning. might be the most clueless of the bunch minus JJ, who knows literally nothing. guys, its not hard. $EYPT sealed your fate.

0 · Reply

newmoneyking Sep. 16 at 1:37 PM

$EYPT this should have SSR on today, thus a little rebound here and there. Could be wrong.

1 · Reply

BLtheKid Sep. 16 at 1:30 PM

$EYPT drkyle clown blocked

2 · Reply

DrKyle Sep. 16 at 11:43 AM

$EYPT today shouldn't be as bad...likely 3.35-3.45 close

0 · Reply

SecoTrader Sep. 16 at 11:21 AM

$EYPT yeah yesterday was indeed hard to endure. I am expecting a significant rebound today, if Mr. Market allows for it LOL

0 · Reply

hellomynameiz Sep. 16 at 10:23 AM

$EYPT the stock has been a repeat kick in the nuts

0 · Reply

Morpheus87 Sep. 16 at 7:03 AM

$EYPT cmon, get back above the 4 - yesterday was insane

0 · Reply

MasterChiefCov Sep. 16 at 3:39 AM

$EYPT Keep the faith folks LUCIA is yet to read out make or break!

0 · Reply

Jjarnold44 Sep. 16 at 2:17 AM

$EYPT How many longs have been around since the reverse split? You are basically back to .37 cents right?

0 · Reply

JaumeIII Sep. 16 at 12:32 AM

$EYPT and $OCUL will both have a hard time going against current antivegf treatments. TKI’s work but not floating around the vitreous for 6-9 months. Right drug, wrong delivery. Eypt happened, ocul is next.

4 · Reply

Skipper_Jack Sep. 15 at 11:54 PM

$EYPT

0 · Reply

Sanjaynaik2011 Sep. 15 at 11:36 PM

$EYPT WHERE'S THE BOTTOM OF THIS STOCK?? NO MATTER HOW MUCH YOU PUT IN THIS TRASH, IT DRAINS EVERY SINGLE CENT. MAYBE THIS MIGHT END UP ON OTC MARKET VERY SOON AT THIS RATE!! CEO IS A BIGGEST PIECE OF TRASH AND THE STOCK FOLLOWS THE TRASH!!

0 · Reply

Guitars7 Sep. 15 at 9:23 PM

$EYPT first bought shares @4.37 day of crash only to see over six dollars SP few days later….I had ten 5.00 calls for this Friday also. I got greedy thinking this would be 7-8 no time Today completely destroyed my calls for Friday and my shares are now heavy bags Humble pie tastes like crap

1 · Reply

KimboIce Sep. 15 at 8:50 PM

$EYPT CFO is signaling at a non-dilutive royal pharma deal (similar to KOD) if Lucia and NDA submission successful. The current share price is a gift if Lucia succeeds.

2 · Reply

Momikhan Sep. 15 at 8:42 PM

$EYPT shorts be very careful your funeral can be announced anytime soon i would suggest you use EYPT products for your vision don't be blind completely ! Ultra Bullish

1 · Reply

Ivorthedriver Sep. 15 at 8:36 PM

$EYPT There are 3 days I give a shit about the PPS of ANY stock: The day I buy; The day I sell; The day they dilute. The rest is noise. All the best, Ivor

0 · Reply

rizzato Sep. 15 at 8:15 PM

$EYPT EyePoint Inc at Morgan Stanley Global Healthcare Conference was better to go to eat a pizza than to be there is time to hire some good marketing director before to see the share price at 1

0 · Reply

rizzato Sep. 15 at 8:06 PM

$EYPT for sure they have to find the way to support the share price because even if Lucia will pass the test if they doesn't do nothing now shorters will push us down deeper and deeper as already said it doesn't mean nothing driving around the usa for some big investor day if you are not able to convince people about the validity of your product . the result is that fucking drop with no sense at all

1 · Reply

Market Cap	1.47B
Revenue (ttm)	43.27M
Net Income (ttm)	-130.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-302.45%
Debt to Equity Ratio	0.00

Volume	1,429,818
Avg Vol	1,347,702
Day's Range	N/A - N/A
Shares Out	82.79M
Stochastic %K	98%
Beta	1.67
Analysts	Strong Sell
Price Target	$34.00